Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow scPharmaceuticals Inc.

Get SEC filing alerts via email and in your feed for scPharmaceuticals Inc.

SCPH

scPharmaceuticals Inc.

About scPharmaceuticals Inc.

scPharmaceuticals Inc. develops innovative, patient-centric therapies for cardiorenal health, focusing on subcutaneous delivery of diuretics like FUROSCIX. Its products aim to reduce hospitalizations, lower healthcare costs, and improve outpatient care for heart failure and kidney disease patients. The company leverages proprietary formulations, drug-device combinations, and a specialized sales infrastructure to commercialize its FDA-approved and pipeline therapies globally.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from scPharmaceuticals Inc.

1
1
scPharmaceuticals Inc. scPharmaceuticals Reports $16M in Product Revenues, Faces $18M Net Loss in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
scPharmaceuticals Inc. scPharmaceuticals Reports 93% Revenue Growth to $11.8M in Q1 2025 Amid Increased Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
scPharmaceuticals Inc. ScPharmaceuticals Reports $85.1 Million Net Loss for 2024, Despite Revenue Growth from FUROSCIX

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
scPharmaceuticals Inc. scPharmaceuticals Reports Revenue Growth, Net Loss in Q3 2024, Amid Ongoing Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments